Genscript BiotechGNNSF 66 Net Margin % is -115.11% as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, Genscript Biotech ranks better than 54.2% on this metric.
The historical rank and industry rank for Genscript Biotech's Net Margin % or its related term are showing as below:
GNNSF'
s Net Margin % Range Over the Past 10 Years
Min: -73.19 Med: -26.24 Max: 498.22
Current: -55.29
GNNSF's Net Margin % is ranked better than 54.2% of 941
companies
in the Biotechnology industry
Industry Median: -88.3
vs GNNSF: -55.29
Genscript Biotech (OTCPK:GNNSF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Genscript Biotech Net Margin % Related Terms
Genscript Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Genscript Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Net Margin % of -115.11% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #431 out of 941 companies in the Biotechnology industry, placing it in the top 45.8%.
Is Genscript Biotech's Net Margin % too high?
Genscript Biotech's current Net Margin % is -115.11%. Based on the distribution chart, Genscript Biotech ranks #431 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #431 out of 941 companies for Net Margin %. This puts Genscript Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Net Margin % is -115.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Net Margin % is -115.11%. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Net Margin % is -115.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Net Margin %: -115.11%
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
